

**Content validity:** The scoring instrument was applied to infants (n = 115) by HCPs who were asked to rate each item/domain for clinical relevance. All items/domains were assessed as relevant. However there were substantial missing data for two domains (chest auscultation/blood gas analysis) as certain HCP groups could not undertake these procedures. These two domains were consequently removed.

**Cognitive interviewing:** HCPs (n = 15) were interviewed in order to assess comprehension, interpretation and how they arrived at their responses for each item/domain in the scoring instrument. Understanding of medical vocabulary was assessed. 'Sub-sternal recession' was removed and 'anuric' changed to 'not passed urine'.

**Construct validity & paediatrician inter-rater reliability:** HCPs applied the scoring instrument to infants (n = 128) whilst two senior doctors assessed whether the infant had 'mild', 'moderate' or 'severe' bronchiolitis. Cut points within the score have now been established for 'mild', 'moderate' and 'severe' bronchiolitis. **Conclusions** We have developed and partially validated a clinical severity score for infants with bronchiolitis. Criterion and reliability testing of the score is planned for the 2013/14 bronchiolitis season. Responsiveness to change will be assessed in a future clinical trial.

## REFERENCES

1. Bialy L *et al.* The Treatment of Bronchiolitis in Children: An Overview of Reviews. *Evid.-Based Child Health* 2011; 6: 258–275
2. Damore D *et al.* Prospective multicentre bronchiolitis study: predicting ICU admissions. *Acad Emerg Med* 2008; 15(10): 887–894.

## S76 NON-INVASIVE POSITIVE PRESSURE VENTILATION TO REDUCE CHILDHOOD MORTALITY FROM ACUTE RESPIRATORY FAILURE IN RURAL GHANA

<sup>1,2</sup>RE Balfour-Lynn, <sup>3</sup>G Marsh, <sup>4</sup>D Gorayi, <sup>5</sup>E Elahi, <sup>2,3</sup>JM LaRovere; <sup>1</sup>University College London Medical School, London, United Kingdom; <sup>2</sup>Boston Children's Hospital, Boston, USA; <sup>3</sup>Royal Brompton and Harefield Hospital NHS Foundation Trust, London, UK; <sup>4</sup>Tumu District Hospital, Tumu, Ghana; <sup>5</sup>Mt. Sinai School of Medicine, New York, USA

10.1136/thoraxjnl-2013-204457.83

**Introduction and Objectives** Acute respiratory failure (ARF) is a major cause of mortality in the developing world, exacerbated by resource limitation. Non-invasive positive pressure ventilation (NIPPV) is a potential simple way to reduce mortality, and whilst established in adults, evidence in children is lacking.

**Methods** The study was conducted in Tumu District Hospital in Northern Ghana, which serves a catchment of 56,000 and has an under-5 Mortality of 142 per 1000 live births. Two Nippy Junior paediatric pressure controlled portable ventilators, chosen for ease of use and robustness, were used along with finger monitors to measure oxygen saturation and heart rate. Training of nurses, the nurse anaesthetist and the doctor was achieved with interactive lectures, hands-on workshops and competency assessment over 3 days in November 2011 and April 2012. Laminated guides attached to each machine outlined criteria to commence, escalate and wean NIPPV. Criteria for commencing NIPPV were based on respiratory rate, oxygen saturation, intercostal recession and expiratory grunting.

**Results** In the initial 4 months of NIPPV use, 657 children under 5 were admitted with 11 deaths, of whom 84 received NIPPV with 3 deaths. In the subsequent 9 months, NIPPV was used in 46 children and 11 adults, with no deaths. Of 140 patients ventilated in 2012, 106 (76%) were under five and 60 (43%) under the age of two. There were 2 deaths from malaria/

sepsis with an overall mortality of 1.4% (1.9% <5 years). Primary diagnoses by age as best available are displayed in figure 1. No complications were reported apart from discomfort in some patients. Patients were ventilated for shorter periods than usual in the developed world. Ventilation times were notably shorter in malaria patients. Those with respiratory tract infections and pneumonia tend to be ventilated longer and were often more comfortable with ventilation for longer periods at a time.

**Conclusions** This feasibility study shows NIPPV for ARF in children in a rural setting can be delivered safely with minimal training and appears to impact significantly on mortality in those under 5.

Diagnosis	0-5 years n = 106	5-16 years n = 23	>16 years n = 11
Malaria	40 (38%)	10 (43%)	0
Septicaemia	27 (25%)	4 (17%)	0
Pneumonia/Bronchiolitis	16 (15%)	3 (14%)	4 (36%)
Gastroenteritis	11 (10%)	0	0
Anaemia	10 (9%)	3 (14%)	0
Asthma	2 (2%)	1 (4%)	5 (45%)
Other		2 (8%)	2 (19%)

Abstract S76 Figure 1.

## S77 BENCHMARKING STANDARDS IN PAEDIATRIC PLEURAL INFECTION MANAGEMENT

<sup>1</sup>AM Long, <sup>2</sup>J Smith-Williams, <sup>1</sup>S Mayell, <sup>1</sup>J Couriel, <sup>1</sup>MO Jones, <sup>1</sup>PD Losty; <sup>1</sup>Alder Hey Children's Hospital, Liverpool, UK; <sup>2</sup>University of Liverpool, Liverpool, UK

10.1136/thoraxjnl-2013-204457.84


**Introduction and Objectives** In our centre patients are managed using a protocol-driven integrated-care pathway. Intra-pleural urokinase is administered via a fine bore chest-drain as primary therapy for significant pleural disease. We analysed patient outcomes with this approach to benchmark standards of care whilst examining patterns of disease severity with introduction of the pneumococcal conjugate vaccine. In addition we aimed to identify factors associated with failure of fibrinolytic therapy, defined as the need for a second intervention, (second chest-drain, VATS or thoracotomy).

**Methods** Medical case-records were reviewed on all children managed at a tertiary centre from Jan 2006-Dec 2012. We examined outcomes on all patients including those with significant medical comorbidities. Data were analysed using binary logistic regression in order to try to identify factors associated with therapy failure, (SPSS Version 20). The effect of; age, comorbidities, number of days of intravenous antibiotics prior to drainage, number of doses of urokinase given and whether initial imaging, (plain radiograph, ultrasound or CT), showed evidence of necrotising disease.

**Results** A total of 242 children were treated; age range 4 months-19 yrs; median 4 yrs. We observed a decreasing number of children presenting year-on-year with complicated pleural infection, (Figure 1). The vast majority of children were managed without surgery using either antibiotics alone (28%), or a fine-bore chest-drain and urokinase (70%), with good outcome. Only 2% children required a primary thoracotomy whilst 14.6% failed fibrinolytic therapy and required a second intervention. The only factor that appeared to predict failure was the suspicion of necrotising disease on initial imaging (p = 0.01, OR 0.11). Median length-of-stay for all children, including those with medical co-morbidity, was 10 days (range 1–118 days).

**Conclusions** We have observed a decreasing incidence of complicated pleural infection at this centre since 2006. Good patient

outcome supports timely management of children using an integrated care-pathway led by a multidisciplinary team. The vast majority of children may be safely managed without surgery.



**Abstract S77 Figure 1.** Number of inpatient admissions and primary management by year.

## Managing pleural effusions

### S78 EVALUATION OF AN AMBULATORY PLEURAL SERVICE: COSTS AND BENEFITS

<sup>1</sup>RL Young, <sup>2</sup>R Bhatnagar, <sup>3</sup>JD Mason, <sup>4</sup>AJ Benson, <sup>5</sup>CE Hooper, <sup>2</sup>AO Clive, <sup>6</sup>N Zahan-Evans, <sup>6</sup>AJ Morley, <sup>6</sup>JE Harvey, <sup>6</sup>ARL Medford, <sup>2</sup>NA Maskell; <sup>1</sup>University of Bristol Medical School, Bristol, United Kingdom; <sup>2</sup>University of Bristol Academic Respiratory Unit, Bristol, United Kingdom; <sup>3</sup>Department of Clinical Coding, North Bristol NHS Trust, Bristol, United Kingdom; <sup>4</sup>Finance Department, North Bristol NHS Trust, Bristol, United Kingdom; <sup>5</sup>Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom; <sup>6</sup>North Bristol Lung Centre, North Bristol NHS Trust, Bristol, United Kingdom

10.1136/thoraxjnl-2013-204457.85

**Background** Outpatient management of undiagnosed pleural effusions is increasing. Payment for managing these patients is usually based on standard outpatient Healthcare Resource Group (HRG) codes. For 2013/14, a new Best Practice Tariff (BPT) of £1534 has been introduced to further disincentivize emergency inpatient management. We audited our service and examined what effects this tariff may have when applied.

**Methods** Our well-established tertiary pleural service serves a local population of around 540,000. New patients are seen in a weekly pleural clinic or in a daily respiratory admission avoidance (Hot) clinic, which had standard 2012/13 tariffs of £223 and £334 respectively. The service sees approximately 150 new effusion patients per year in clinic and 3 new patients per week in Hot. Around 50 medical thorascopies and 60 indwelling pleural catheter insertions are performed each year.

We audited randomly selected patients from our large, prospectively-maintained database. All audited patients were seen as new pleural effusion referrals between 2008 and 2012. Diagnosis was confirmed after a minimum of 12 months' follow-up.

**Results** 146 patients were audited. Median age 76(range 21–93), 71% male. Final diagnoses were mesothelioma (n = 28,19%), lung cancer (n = 10,7%), breast cancer (n = 13,9%), other cancer (n = 31,21%), pleural infection (n = 15,10%), benign pleuritis (n = 11,8%) and other (n = 38,26%). 92% of patients avoided direct admission following their initial clinic appointment.

115 patients (79%) underwent ultrasound-guided pleural aspiration at their initial appointment and 63(43%) patients underwent subsequent pleural biopsy. For patients with malignancy, diagnostic sensitivity on first fluid cytology was 27% (adenocarcinoma n = 15,80%; mesothelioma n = 21,5%), and 93%(25/27) for medical thoracoscopy biopsy. Histological/cytological diagnosis took a median of 20 days (IQR 10–33) from presentation. There were no significant procedural complications noted (bleeding, pneumothorax, empyema). 97%(58/60) of patients surveyed rated the service as either very good or excellent.

**Conclusions** Ambulatory management of undiagnosed effusions is efficacious, avoids hospitalisation in the vast majority and is preferred by patients. The 2013/14 pleural effusion BPT promotes admission avoidance by encouraging appropriate outpatient management. Trust reimbursement for practising in this way should facilitate enough resource to enable new pleural services to be established where required.

### S79 COMPARING THE QUALITY OF LIFE AND COST-EFFECTIVENESS OF INDWELLING PLEURAL CATHETER VS. TALC PLEURODESIS FOR MALIGNANT PLEURAL EFFUSIONS

<sup>1</sup>E Penz, <sup>2</sup>E Mishra, <sup>3</sup>H Davies, <sup>1</sup>B Manns, <sup>4</sup>RF Miller, <sup>2</sup>N Rahman; <sup>1</sup>University of Calgary, Calgary, Canada; <sup>2</sup>Oxford University, Oxford, United Kingdom; <sup>3</sup>University Hospital of Wales, Cardiff, United Kingdom; <sup>4</sup>University College London, London, United Kingdom

10.1136/thoraxjnl-2013-204457.86

**Abstract S78 Table 1.** Estimates of income using old and new tariffs based on yearly patient numbers and audit data

Type of encounter	Number	2012 – 2013tariff	2013 – 2014 BPT tariff	Notes
Outpatient/Hot new effusion	300	[300*(223+334/2)] = £83,550*0.92 = £76,866	a. [300*0.70]*1534] = £322,140*0.92 = £296,369 b. [(300*0.3)*(189+329/2)] = £23,310*0.92 = £21,445 a+b = £317,814	Assumed 70% of patients undergo aspiration at first appointment (therefore eligible for BPT), and 8% need admission (therefore not billed as outpatients)
Subsequent aspiration	60	60*544 = £32,640	18*544 = £9792	Assumed 20% go on to have aspiration later
IPC insertion	60	60*544 = £32,640	60*544 = £32,640	All IPCs inserted as day case
Medical thoracoscopy	50	50*[(544+2153)/2] = £67,425	50*[(544+2153)/2] = £67,425	Assumed 50% of patients receive talc
<b>12 MONTH TOTAL</b>		<b>£209,571</b>	<b>£427,671</b>	<b>Extra income£218,100</b>

CODES & TARIFFS: Diagnostic thoracoscopy (T11.1, HRG DZ06Z, £544); Thoracoscopy with talc (T10.2, HRG DZ04B, £2153); IPC insertion (T12.4, HRG DZ06Z, £544); Aspiration (T12.3, HRG DZ06Z, £544); Respiratory o/p first attendance (WF01B, £223 in 12/13, £189 in 13/14); HOT clinic (locally agreed £334 in 12/13, £329 in 13/14). BPT aspirations must occur on elective list after initial assessment.